Biocytogen Pharmaceuticals (Beijing) just released its Q3 2026 results, and the market had already been punishing the stock, with the share price down about 45% over the past month heading into today’s close at HK$38.30. The headline this quarter is a profit squeeze, with basic earnings per share at 0.158 CNY on net income of about C¥71.4 million, which was well below the prior quarter’s level.

Traders have been pricing in worry for weeks. The key question now is whether that earlier selloff already reflected this margin pressure or if investor sentiment is still running ahead of the actual numbers.

Love the science behind Biocytogen Pharmaceuticals (Beijing) but worried about pressure on earnings and…